Citations

Clear

16 citation(s) found for "Smith, Richard J H".

Evolving role of the emergency medicine pharmacist in tele-emergency medicine
Smith, Cole, Sultan, Sania, Raheem, Shazia, Mattson, Alicia E , Smith, Cole, Sultan, Sania

Mayo Clinic

American Journal of Health-System Pharmacy | July 31, 2025 | Volume: 82 | Issue: 24 | Pages: 1411-1415

10.1093/ajhp/zxaf204 | PMID 40749092 Get It

(099) UNDER PRESSURE: STRESS IS NEGATIVELY ASSOCIATED WITH LIBIDO AND INTERCOURSE FREQUENCY
Seyer, A, Belarmino, André , Civello, Daniel, Nolte, D, Kenfield, Stacey A. , Smith, James Richard , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.097 Get It

Abstract Introduction Undergoing fertility testing can be a stressful event in a couple's life. This can impact multiple aspects of life, including sex. Objective To evaluate the relationship between stress and sexual function in men undergoing fertility testing. Methods We performed a review of a prospectively maintained database of men utilizing a mail-in semen analysis test system developed by Fellow Health, Inc. Those included consented to participate in research, were 18 or older, and completed survey questionnaires on both their quality of life and sexual function. Stress level (low, moderate, or high stress) was determined using the validated Perceived Stress Scale (PSS) 10-question survey. The sexual function survey assessed libido, orgasmic and ejaculatory dysfunction, intercourse frequency, Erection Hardness Score, and IIEF-5 score. Descriptive statistics were reported and chi-squared and t-tests were used to determine statistical significance at the 0.05 alpha level. Results A total of 2077 men undergoing fertility testing were included in this study. 50.2% reported moderate stress levels and 2.6% reported high stress levels. Those with low stress were older than those with moderate or high stress (average 35.4 vs. 34.3 and 34.0 years, respectively; p < 0.01). Men with high stress levels were more likely to report a “poor” or “terrible” libido (31.4%) compared to those with moderate or low stress, 17.2% and 9.5%, respectively (p < 0.01). Stress was highly associated with weekly intercourse frequency (p < 0.01): among men with high levels of stress, 25.5% reported having sex less than once a week compared to 6.0% of men with low stress. Likewise, no highly stressed men reported having sex more than six times per week compared to 2.8% of men with low stress. Whereas 80.4% of men with low stress were evaluated to have “No signs of ED” by the IIEF-5, the same was true for only 62.3% of moderately stressed men and 56.0% of highly stressed men (p < 0.01). Conclusions More than half of men undergoing fertility testing report increased levels of stress, which is negatively associated with libido and erectile function. In men seeking fertility evaluation, lifestyle factors such as stress levels should be assessed to identify patients who may benefit from stress management strategies. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Fellow Health.
Moderate Aortic Valve Stenosis Is Associated With Increased Mortality Rate and Lifetime Loss: Systematic Review and Meta‐Analysis of Reconstructed Time‐to‐Event Data of 409 680 Patients
Jacquemyn, Xander , Strom, Jordan B. , Strange, Geoff , Playford, David , Stewart, Simon , Kutty, Shelby , Bhatt, Deepak L. , Bleiziffer, Sabine , Pellikka, Patricia A. , Pîbarot, Philippe , Grubb, Kendra J , Pellikka, Patricia A , Clavel, Marie-Annick , Pibarot, Phillippe , Mentias, Amgad , Serna-Gallegos, Derek , Sá, Michel Pompeu , Sultan, Ibrahim , Strom, Jordan B , Bhatt, Deepak L , Clavel, Marie‐Annick , Sá, Michel Pompeu , Sultan, Ibrahim

Mayo Clinic

Journal of the American Heart Association | May 3, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.033872 | PMID 38700000 Get It

Background The mortality risk attributable to moderate aortic stenosis (AS) remains incompletely characterized and has historically been underestimated. We aim to evaluate the association between moderate AS and all‐cause death, comparing it with no/mild AS (in a general referral population and in patients with heart failure with reduced ejection fraction). Methods and Results A systematic review and pooled meta‐analysis of Kaplan–Meier‐derived reconstructed time‐to‐event data of studies published by June 2023 was conducted to evaluate survival outcomes among patients with moderate AS in comparison with individuals with no/mild AS. Ten studies were included, encompassing a total of 409 680 patients (11 527 with moderate AS and 398 153 with no/mild AS). In the overall population, the 15‐year overall survival rate was 23.3% (95% CI, 19.1%–28.3%) in patients with moderate AS and 58.9% (95% CI, 58.1%–59.7%) in patients with no/mild aortic stenosis (hazard ratio [HR], 2.55 [95% CI, 2.46–2.64]; P <0.001). In patients with heart failure with reduced ejection fraction, the 10‐year overall survival rate was 15.5% (95% CI, 10.0%–24.0%) in patients with moderate AS and 37.3% (95% CI, 36.2%–38.5%) in patients with no/mild AS (HR, 1.83 [95% CI, 1.69–2.0]; P <0.001). In both populations (overall and heart failure with reduced ejection fraction), these differences correspond to significant lifetime loss associated with moderate AS during follow‐up (4.4 years, P <0.001; and 1.9 years, P <0.001, respectively). A consistent pattern of elevated mortality rate associated with moderate AS in sensitivity analyses of matched studies was observed. Conclusions Moderate AS was associated with higher risk of death and lifetime loss compared with patients with no/mild AS.
Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus
Čarná, Mária , Onyango, Isaac G. , Katina, Stanislav , Holub, Dušan , Nezvedová, Markéta , Jha, Durga , Nedelská, Zuzana , Lacovich, Valentina , Houbrechts, Ruben, Garcia‐Mansfield, Krystine , David‐Dirgo, Victoria , Texlova, Kateřina, Bakkar, Nadine , Pertierra, Lucía , Vinkler, Mojmír, Marková, Hana, Laczó, Jan , Kohoutková, Marcela Hortová , Frič, Jan , Forte, Giancarlo , Bělašková, Silvie , Seyfried, Nicholas T. , Bowser, Robert , Pirrotte, Patrick , Dammer, Eric B. , Limbäck‐Stokin, Clara, Stokin, Gorazd B. , Nedelska, Zuzana , Dammer, Eric B , Novotný, Jan , Vyvere, Thijs Vande , Sharma, Ritin , Vyhnálek, Martin , Chaves, Hernán , Sheardová, Kateřina , Kaňovský, Petr , Damborský, Jiřı́ , Hort, Jakub , Sevlever, Gustavo Emilio , Rissman, Robert A. , Smith, Richard Alan , Hajduch, Marian , Spáčil, Zdeněk

Mayo Clinic

Alzheimer's & Dementia | February 24, 2023 | Volume: 19 | Issue: 8 | Pages: 3537-3554

10.1002/alz.12970 | PMID 36825691 Get It

Abstract The choroid plexus (ChP) produces and is bathed in the cerebrospinal fluid (CSF), which in aging and Alzheimer's disease (AD) shows extensive proteomic alterations including evidence of inflammation. Considering inflammation hampers functions of the involved tissues, the CSF abnormalities reported in these conditions are suggestive of ChP injury. Indeed, several studies document ChP damage in aging and AD, which nevertheless remains to be systematically characterized. We here report that the changes elicited in the CSF by AD are consistent with a perturbed aging process and accompanied by aberrant accumulation of inflammatory signals and metabolically active proteins in the ChP. Magnetic resonance imaging (MRI) imaging shows that these molecular aberrancies correspond to significant remodeling of ChP in AD, which correlates with aging and cognitive decline. Collectively, our preliminary post‐mortem and in vivo findings reveal a repertoire of ChP pathologies indicative of its dysfunction and involvement in the pathogenesis of AD. Highlights Cerebrospinal fluid changes associated with aging are perturbed in Alzheimer's disease Paradoxically, in Alzheimer's disease, the choroid plexus exhibits increased cytokine levels without evidence of inflammatory activation or infiltrates In Alzheimer's disease, increased choroid plexus volumes correlate with age and cognitive performance
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.
TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study
Bowles, Bradley , Ferrer, Alejandro , Nishimura, Carla, Rey, Tristan, Leheup, Bruno, Sullivan, Jennifer A. , Schoch, Kelly, Stong, Nicholas , Agolini, Emanuele , Cocciadiferro, Dario , Williams, Abigail , Cummings, Alex, Genovese, Silvia , Roadhouse, Chelsea, Network, Undiagnosed Diseases, Wentzensen, Ingrid M. , Li, Chumei , Babovic‐Vuksanovic, Dusica , Lanpher, Brendan C. , Dentici, Maria Lisa , Hamm, J. Austin, Shashi, Vandana , Gérard, Bénédicte , Bloch‐Zupan, Agnès , Smith, Richard J. , Klee, Eric W. , Oglesbee, Devin , McCauley, Jacob L. , Nelson, Stanley F. , Azamian, Mahshid S. , Martínez-Agosto, Julián A. , Chang, Ta Chen , Blue, Elizabeth , Woods, Jeremy D. , Baldridge, Dustin , Pinto E Vairo, Filippo, Sullivan, Jennifer , Agolini, Emanuele , Loddo, Sara , Genovese, Silvia , Li, Chumei , Babovic-Vuksanovic, Dusica, Dentici, Maria Lisa , Ankala, Arun , Radio, Francesca Clementina , Bloch-Zupan, Agnes , Oglesbee, Devin , Baldridge, Dustin , Stong, Nicholas , Ferrer, Alejandro , McCauley, Jacob L , Vairo, Filippo Pinto e , McWalter, Kirsty , Network, Undiagnosed Diseases, Dallapiccola, Bruno , Radio, Francesca Clementina

Mayo Clinic

American Journal of Medical Genetics Part A | May 27, 2021 | Volume: 185 | Issue: 8 | Pages: 2417-2433

10.1002/ajmg.a.62347 | PMID 34042254 Get It

AbstractBiallelic loss‐of‐function variants in the thrombospondin‐type laminin G domain and epilepsy‐associated repeats (TSPEAR) gene have recently been associated with ectodermal dysplasia and hearing loss. The first reports describing a TSPEAR disease association identified this gene is a cause of nonsyndromic hearing loss, but subsequent reports involving additional affected families have questioned this evidence and suggested a stronger association with ectodermal dysplasia. To clarify genotype–phenotype associations for TSPEAR variants, we characterized 13 individuals with biallelic TSPEAR variants. Individuals underwent either exome sequencing or panel‐based genetic testing. Nearly all of these newly reported individuals (11/13) have phenotypes that include tooth agenesis or ectodermal dysplasia, while three newly reported individuals have hearing loss. Of the individuals displaying hearing loss, all have additional variants in other hearing‐loss‐associated genes, specifically TMPRSS3, GJB2, and GJB6, that present competing candidates for their hearing loss phenotype. When presented alongside previous reports, the overall evidence supports the association of TSPEAR variants with ectodermal dysplasia and tooth agenesis features but creates significant doubt as to whether TSPEAR variants are a monogenic cause of hearing loss. Further functional evidence is needed to evaluate this phenotypic association.
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

Mayo Clinic

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 | PMID 33405268 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre, Lauren A. , Yang, Eric H. , Cheng, Richard K. , DeCara, Jeanne M. , Liu, Jennifer E. , Rudski, Lawrence , Strom, Jordan B. , Barac, Ana , Bucciarelli‐Ducci, Chiara , Lenneman, Carrie , Villarraga, Hector R. , Ismail‐Khan, Roohi , Ky, Bonnie , Leja, Monika, Scherrer‐Crosbie, Marielle , Liu, Jennifer E , Rudski, Lawrence G , Strom, Jordan B , Thavendiranathan, Paaladinesh , Barac, Ana , Zaha, Vlad G , Bucciarelli-Ducci, Chiara , Ellahham, Samer , Deswal, Anita M , Lenneman, Carrie , Villarraga, Hector R , Blaes, Anne H , Ismail-Khan, Roohi , Ky, Bonnie , Scherrer-Crosbie, Marielle , Yang, Eric , Cheng, Richard , Dent, Susan , Blaes, Anne

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 3, 2020 | Volume: 113 | Issue: 5 | Pages: 513-522

10.1093/jnci/djaa177 | PMID 33179744 Get It

Abstract In response to the coronavirus disease 2019 (COVID-19) pandemic, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients—individuals with an active or prior cancer history and with or at risk of cardiovascular disease—are a rapidly growing population who are at increased risk of infection, and experiencing severe and/or lethal complications by COVID-19. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, and pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic.
Genetic Abnormalities in Complement Regulating Proteins in C3 Glomerulopathy
Smith, Richard J H, Bu, Fengxiao , Borsa, Nicolò Ghiringhelli , Jones, Michael, Bierer, Amanda O., Meyer, Nicole C. , Frees, Kathy, Weaver, Amy , Sethi, Sanjeev , Ravindran, Aishwarya , Smith, Richard J H, Fervenza, Fernando C. , Zhang, Yuzhou , Jones, Michael, Weaver, Amy, Nester, Carla

Mayo Clinic

American Journal of Clinical Pathology | September 21, 2018 | Volume: 150 | Issue: suppl_1 | Pages: S131-S131

10.1093/ajcp/aqy102.313 Get It